Abbott Laboratories
ABT · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $234,261 | $236,720 | $231,769 | $195,872 |
| - Cash | $7,511 | $6,951 | $6,532 | $7,616 |
| + Debt | $12,941 | $13,437 | $13,242 | $15,275 |
| Enterprise Value | $239,691 | $243,206 | $238,479 | $203,531 |
| Revenue | $11,369 | $11,142 | $10,358 | $10,974 |
| % Growth | 2% | 7.6% | -5.6% | – |
| Gross Profit | $6,338 | $6,288 | $5,444 | $5,598 |
| % Margin | 55.7% | 56.4% | 52.6% | 51% |
| EBITDA | $3,015 | $3,048 | $2,668 | $2,989 |
| % Margin | 26.5% | 27.4% | 25.8% | 27.2% |
| Net Income | $1,644 | $1,779 | $1,325 | $9,229 |
| % Margin | 14.5% | 16% | 12.8% | 84.1% |
| EPS Diluted | 0.94 | 1.01 | 0.758 | 5.27 |
| % Growth | -6.9% | 33.2% | -85.6% | – |
| Operating Cash Flow | $2,787 | $2,047 | $1,417 | $2,868 |
| Capital Expenditures | -$496 | -$502 | -$484 | -$720 |
| Free Cash Flow | $2,291 | $1,545 | $933 | $2,148 |